US Taps Negotiated Drug Prices in J&J, Bristol Myers Legal Fight

The Biden administration for the first time is underscoring the list of 10 Medicare negotiated drug prices in the pharmaceutical industry’s legal battle against the program, arguing that back-and-forth talks took place between the government and manufacturers.

Johnson & Johnson and Bristol Myers Squibb Co.'s argument that the US Department of Health and Human Services’ Medicare Drug Price Negotiation Program forces them to sell their drugs to the government at below-market value and agree to program participation is incorrect, the agency wrote in an opposition brief Monday before the US Court of Appeals for the Third Circuit.

“The negotiations did ...